AR073548A1 - Compuestos derivados de diazol y triazol, composiciones y uso de los mismos para modular los niveles de acido urico - Google Patents
Compuestos derivados de diazol y triazol, composiciones y uso de los mismos para modular los niveles de acido uricoInfo
- Publication number
- AR073548A1 AR073548A1 ARP090103415A ARP090103415A AR073548A1 AR 073548 A1 AR073548 A1 AR 073548A1 AR P090103415 A ARP090103415 A AR P090103415A AR P090103415 A ARP090103415 A AR P090103415A AR 073548 A1 AR073548 A1 AR 073548A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- butyl
- cyclopropylmethyl
- propyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
Abstract
Se describen en la presente compuestos utiles en la modulacion de los niveles de ácido urico en la sangre, formulaciones que los contienen y métodos para hacerlos y usarlos. En algunas realizaciones, un compuesto descrito en la presente se usa en el tratamiento o prevencion de enfermedades relacionadas a niveles aberrantes de ácido urico. Reivindicacion 1: Un compuesto de la formula (1) o un metabolito, sal farmacéuticamente aceptable, solvato, polimorfo, éster, tautomero o profármaco del mismo, caracterizado porque: T es N o CH; W es O, S, S(O), S(O)2, NH, N(alquilo), CH2, CH2O, CH2S o CH2NH; R1 es H, F, Cl, Br, I, -CH2F, -CF2H, -CF3, -CN, -OH, -NO2, -NH2, -NH(alquilo) , -N(alquil)(alquilo), -SO2CH3, -SO2NH2, -SO2NHCH3, -CO2-alquilo, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alcoxi opcionalmente sustituido, S-alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heterociclo opcionalmente sustituido, arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; a es 0, 1 o 2; Ra es H o alquilo C1-3; Ra' es H o alquilo C1-3; o Ra y Ra' junto con el átomo de carbono al cual se enlazan forman un anillo de 3, 4, 5 o 6 miembros opcionalmente sustituido, que comprende opcionalmente 1 o 2 heteroátomos seleccionados de O, N y S; Rb, Rc, Re, y Rf son cada uno independientemente H, F, Cl, Br, I, CF3, CN, alquilo, cicloalquilo, ciclopropilmetilo, NH2, NHR', NR'R'', OH, OR', SH, SR', C(O)R', CO2H, COOR', CONH2, CONHR', CONR'R'', SO3H, S(O)2R', S(O)2NH2, S(O)2NHR', S(O)2NR'R'', arilo, heterociclilo o heteroarilo; Rd es H, F, Cl, Br, I, CF3, CN, NH2, NHR', NR'R'', OH, OR', SH, SR', C(O)R', CO2H, COOR', CONH2, CONHR', CONR'R'', SO3H, S(O)2R', S(O)2NH2, S(O)2NHR', S(O)2NR'R'', arilo, heterociclilo o heteroarilo; R' es metilo, etilo, n-propilo, i-propilo, n-butilo, i-butilo, s-butilo, t-butilo, ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo, ciclopropilmetilo o fenilo; R'' es metilo, etilo, n-propilo, i-propilo, n-butilo, i-butilo, s-butilo, t-butilo, ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo, ciclopropilmetilo o fenilo; R' y R'' junto con el átomo de nitrogeno al cual se enlazan forman un anillo heterocíclico de 4, 5 o 6 miembros saturado o no saturado, opcionalmente sustituido; o Rb y Rc, o Rc y Rd, o Rd y Re, o Re y Rf junto con los dos átomos de carbono a los cuales se enlazan, forman un anillo de 5, 6 o 7 miembros aromático o no aromático opcionalmente sustituido, que comprende opcionalmente 1 o 2 heteroátomos seleccionados de O, N y S; y en donde los sustituyentes opcionales son cada uno independientemente F, Cl, Br, I, CF3, CN, alquilo, cicloalquilo, ciclopropilmetilo, NH2, NHR', NR'R'', OH, OR', SH, SR', C(O)R', CO2H, COOR', CONH2, CONHR', CONR'R'', SO3H, S(O)2R', S(O)2NH2, S(O)2NHR', S(O)2NR'R'', arilo, heterociclilo o heteroarilo; x es 0 o 1; y es 0 o 1; z es 0 o 1; Rx, Rx', Ry, Ry', Rz y Rz' son cada uno independientemente H, F, Cl, Br, I o alquilo C1-3; o Rx y Rx', o Ry y Ry', o Rz y Rz', o Rx y Ry, o Ry y Rz, o Rx y Rz junto con los átomos de carbono a los cuales se enlazan, forman un anillo de 3-7 miembros no aromático opcionalmente sustituido, que comprende opcionalmente 1 o 2 heteroátomos seleccionados de O, N y S; A es H, C(O)O-B1 o C(O)NH-B2; en donde B1 es H, alquilo C1-6 opcionalmente sustituido o un cation farmacéuticamente aceptable; B2 es H o alquilo C1-6 opcionalmente sustituido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9438808P | 2008-09-04 | 2008-09-04 | |
US18011009P | 2009-05-20 | 2009-05-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR073548A1 true AR073548A1 (es) | 2010-11-17 |
Family
ID=41726354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090103415A AR073548A1 (es) | 2008-09-04 | 2009-09-04 | Compuestos derivados de diazol y triazol, composiciones y uso de los mismos para modular los niveles de acido urico |
Country Status (16)
Country | Link |
---|---|
US (3) | US8193234B2 (es) |
EP (2) | EP2328874A4 (es) |
JP (3) | JP2012502049A (es) |
KR (2) | KR101294872B1 (es) |
CN (3) | CN102186832B (es) |
AR (1) | AR073548A1 (es) |
AU (2) | AU2009289647C1 (es) |
BR (1) | BRPI0918586A2 (es) |
CA (2) | CA2735828C (es) |
EA (2) | EA023500B1 (es) |
HK (1) | HK1160843A1 (es) |
IL (2) | IL211428A0 (es) |
MX (2) | MX2011002449A (es) |
TW (2) | TW201018463A (es) |
WO (2) | WO2010028189A2 (es) |
ZA (3) | ZA201101626B (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003047648A2 (en) | 2001-12-05 | 2003-06-12 | Sagax Inc. | Endovascular device for entrapment of particulate matter and method for use |
CN102186832B (zh) * | 2008-09-04 | 2014-04-02 | 亚德生化公司 | 调节尿酸含量的化合物、组合物及其使用方法 |
US8173690B2 (en) * | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
US8242154B2 (en) * | 2008-09-04 | 2012-08-14 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
WO2010135536A2 (en) | 2009-05-20 | 2010-11-25 | Ardea Biosciences, Inc. | Methods of modulating uric acid levels |
ES2563207T3 (es) * | 2010-01-08 | 2016-03-11 | Ardea Biosciences, Inc. | Formas polimorfas, cristalinas y en mesofases de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4H-1,2,4-triazol-3-iltio)acetato de sodio y sus usos |
EP3659601A1 (en) * | 2010-03-30 | 2020-06-03 | Ardea Biosciences, Inc. | Treatment of gout |
WO2011159732A1 (en) | 2010-06-15 | 2011-12-22 | Ardea Biosciences,Inc. | Treatment of gout and hyperuricemia |
AR081930A1 (es) * | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
WO2011159840A2 (en) | 2010-06-16 | 2011-12-22 | Ardea Biosciences, Inc. | Phenylthioacetate compounds, compositions and methods of use |
EA022301B1 (ru) * | 2010-12-30 | 2015-12-30 | Ардеа Биосайнсиз, Инк. | Полиморфные формы 2-(5-бром-4-(4-циклопропилнафталин-1-ил)-4h-1,2,4-триазол-3-илтио)уксусной кислоты и их применение |
AU2012258860B2 (en) * | 2011-05-24 | 2015-12-03 | Ardea Biosciences, Inc. | Hypertension and hyperuricemia |
US10047050B2 (en) | 2011-11-03 | 2018-08-14 | Ardea Biosciences, Inc. | 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same |
AR091651A1 (es) * | 2012-07-03 | 2015-02-18 | Ardea Biosciences Inc | Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico |
TWI666205B (zh) * | 2012-11-14 | 2019-07-21 | 日商帝人製藥股份有限公司 | 吡啶衍生物 |
CN103389346B (zh) * | 2013-07-18 | 2014-08-06 | 湖北华世通潜龙药业有限公司 | 利用hplc测定非布司他及口服制剂中有关物质的方法 |
CN103588716A (zh) * | 2013-11-22 | 2014-02-19 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的新晶型及其制备方法 |
CA2931430A1 (en) * | 2013-11-22 | 2015-05-28 | Crystal Pharmatech Co., Ltd. | Crystalline forms of lesinurad and its sodium salt |
CN103755651A (zh) * | 2013-12-23 | 2014-04-30 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法 |
CN104292177B (zh) * | 2014-10-07 | 2016-08-17 | 张远强 | 含腈基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途 |
CN104292176B (zh) * | 2014-10-07 | 2016-06-29 | 张远强 | 一种含卤代苯的四氮唑乙酸类化合物、其制备方法和用途 |
CN104292175B (zh) * | 2014-10-07 | 2016-06-22 | 张远强 | 含硝基的四氮唑乙酸类化合物、其制备方法及用途 |
CN104292178B (zh) * | 2014-10-07 | 2016-06-22 | 张远强 | 含四氮唑乙酸类化合物、其制备方法及用途 |
CN104262276B (zh) * | 2014-10-07 | 2016-06-22 | 张远强 | 含卤代苯的四氮唑乙酸类化合物、其制备方法及用途 |
CN104341367B (zh) * | 2014-10-07 | 2016-08-17 | 张远强 | 一类四氮唑乙酸类化合物、其制备方法及用途 |
CN104341365A (zh) * | 2014-10-27 | 2015-02-11 | 张远强 | 卤代三氮唑丙二酸类化合物、其制备方法及用途 |
CN104341362B (zh) * | 2014-10-27 | 2016-07-13 | 张远强 | 三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
CN104326997B (zh) * | 2014-10-27 | 2016-09-21 | 张远强 | 烷氧基取代的三氮唑丙二酸类化合物、其制备方法及用途 |
CN104341363B (zh) * | 2014-10-27 | 2016-08-17 | 张远强 | 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
CN104311498B (zh) * | 2014-10-27 | 2016-04-06 | 张远强 | 烷氧基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
CN104326999B (zh) * | 2014-10-27 | 2017-01-18 | 张远强 | 烷氧基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
CN104326994A (zh) * | 2014-10-27 | 2015-02-04 | 张远强 | 一种腈基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
CN104356078A (zh) * | 2014-10-27 | 2015-02-18 | 张远强 | 卤代三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
CN104326998B (zh) * | 2014-10-27 | 2016-08-17 | 张远强 | 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途 |
CN104370841B (zh) * | 2014-10-27 | 2016-07-13 | 张远强 | 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
CN104326996A (zh) * | 2014-10-27 | 2015-02-04 | 张远强 | 一种硝基取代三氮唑丙二酸类化合物、其制备方法及用途 |
CN104327000B (zh) * | 2014-10-27 | 2016-08-17 | 张远强 | 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
CN104341364A (zh) * | 2014-10-27 | 2015-02-11 | 张远强 | 三氮唑丙二酸类化合物、其制备方法及用途 |
CN104370843B (zh) * | 2014-10-27 | 2016-05-18 | 张远强 | 卤代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
CN104341361B (zh) * | 2014-10-27 | 2017-01-11 | 张远强 | 一种腈基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
CN104326993B (zh) * | 2014-10-27 | 2016-08-17 | 张远强 | 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
CN104326995A (zh) * | 2014-10-27 | 2015-02-04 | 张远强 | 一种腈基取代的三氮唑丙二酸类化合物、其制备方法及用途 |
CN104370842B (zh) * | 2014-10-27 | 2016-07-13 | 张远强 | 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
KR20170110083A (ko) | 2014-12-23 | 2017-10-10 | 인털렉츄얼 프라퍼티 어쏘시에이츠, 엘엘씨 | 경피 투여를 위한 방법 및 제형 |
KR102556608B1 (ko) | 2014-12-29 | 2023-07-17 | 닛뽕 케미파 가부시키가이샤 | Urat1 저해제 |
CN104817562B (zh) * | 2015-04-17 | 2017-05-03 | 东南大学 | 一种具有治疗及预防高尿酸血症或痛风的化合物及其制备方法和应用 |
CN106187926B (zh) * | 2015-04-30 | 2018-11-27 | 天津药物研究院有限公司 | 含二芳基甲烷结构的羧酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途 |
EP3112334A1 (en) | 2015-06-29 | 2017-01-04 | DPx Fine Chemicals Austria GmbH & CoKG | Process for manufacturing 1-cyclopropyl-naphthalenes |
CN108026043A (zh) * | 2015-08-14 | 2018-05-11 | 广东东阳光药业有限公司 | 一种萘环化合物的晶型 |
ES2961901T3 (es) * | 2016-05-23 | 2024-03-14 | Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd | Tiofeno, método de fabricación del mismo y aplicación farmacéutica del mismo |
DK3473617T3 (da) * | 2016-06-17 | 2022-11-28 | Medshine Discovery Inc | Halogeneret forbindelse og aksiale, chirale isomerer deraf |
CN107540619B (zh) * | 2016-06-29 | 2019-08-16 | 天津药物研究院有限公司 | 一种尿酸转运体1抑制剂的制备方法 |
CN107814795B (zh) * | 2016-09-12 | 2020-12-18 | 江苏艾立康药业股份有限公司 | 作为urat1抑制剂的化合物 |
CN108658879A (zh) * | 2017-03-29 | 2018-10-16 | 天津药物研究院有限公司 | 一种urat1抑制剂及其制备方法和用途 |
US20190083386A1 (en) | 2017-09-15 | 2019-03-21 | Ampersand Biopharmaceuticals, Inc. | Methods and formulations for transdermal administration of buffering agents |
CN109134391A (zh) * | 2018-09-21 | 2019-01-04 | 山东大学 | 一种酰基磺酰胺类衍生物及其制备方法与应用 |
CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
CN111763218B (zh) * | 2020-07-14 | 2021-05-28 | 山东大学 | 一种噻吩并嘧啶酮巯乙酸类衍生物及其制备方法与应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2006A (en) * | 1841-03-16 | Clamp for crimping leather | ||
US2008A (en) * | 1841-03-18 | Gas-lamp eok conducting gas pkom ah elevated buhner to one below it | ||
US2009A (en) * | 1841-03-18 | Improvement in machines for boring war-rockets | ||
US4198513A (en) | 1970-09-25 | 1980-04-15 | Merck & Co., Inc. | 1,2,4-Triazoles |
NL7112373A (es) * | 1970-09-25 | 1972-03-28 | ||
US4935438A (en) * | 1987-12-29 | 1990-06-19 | Smithkline Beckman Corporation | Dopamine-β-hydroxylase inhibitors |
CA2251368A1 (en) * | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
GB0028702D0 (en) * | 2000-11-24 | 2001-01-10 | Novartis Ag | Organic compounds |
EA009478B1 (ru) * | 2002-08-23 | 2008-02-28 | Ардеа Байосайенсиз, Инк. | Ненуклеозидные ингибиторы обратной транскриптазы |
US7642277B2 (en) | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
EP1722783A4 (en) * | 2004-03-08 | 2009-08-12 | Wyeth Corp | MODULATORS OF THE ION CHANNEL FUNCTION |
CN1934095A (zh) * | 2004-03-08 | 2007-03-21 | 惠氏公司 | 离子通道调节剂 |
ES2374773T3 (es) * | 2004-08-25 | 2012-02-21 | Ardea Biosciences, Inc. | S-triazolil alfa-mercaptoacetanilidas como inhibidores de la transcriptasa inversa del vih. |
WO2007050087A1 (en) * | 2004-08-25 | 2007-05-03 | Ardea Biosciences, Inc. | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS |
WO2006091506A2 (en) * | 2005-02-24 | 2006-08-31 | Bayer Pharmaceuticals Corporation | Neuropeptide y4 receptor agonists |
WO2007140002A2 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating non-hodgkin's lymphoma |
WO2008057246A2 (en) | 2006-10-26 | 2008-05-15 | Synta Pharmaceuticals Corp. | Method for treating inflammatory disorders |
EP2217577B1 (en) * | 2007-11-27 | 2014-08-06 | Ardea Biosciences, Inc. | Novel compounds and compositions and methods of use |
US8173690B2 (en) * | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
US8242154B2 (en) * | 2008-09-04 | 2012-08-14 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
CN102186832B (zh) | 2008-09-04 | 2014-04-02 | 亚德生化公司 | 调节尿酸含量的化合物、组合物及其使用方法 |
US20120122780A1 (en) | 2009-05-20 | 2012-05-17 | Ardea Biosciences Inc. | Compounds, Compositions and Methods for Modulating Uric Acid Levels |
-
2009
- 2009-09-03 CN CN200980141092.2A patent/CN102186832B/zh active Active
- 2009-09-03 MX MX2011002449A patent/MX2011002449A/es active IP Right Grant
- 2009-09-03 CA CA2735828A patent/CA2735828C/en not_active Expired - Fee Related
- 2009-09-03 WO PCT/US2009/055947 patent/WO2010028189A2/en active Application Filing
- 2009-09-03 AU AU2009289647A patent/AU2009289647C1/en active Active
- 2009-09-03 CN CN2009801411431A patent/CN102186827A/zh active Pending
- 2009-09-03 EA EA201100440A patent/EA023500B1/ru not_active IP Right Cessation
- 2009-09-03 KR KR1020117007535A patent/KR101294872B1/ko active IP Right Grant
- 2009-09-03 BR BRPI0918586A patent/BRPI0918586A2/pt not_active Application Discontinuation
- 2009-09-03 EA EA201100441A patent/EA201100441A1/ru unknown
- 2009-09-03 AU AU2009289646A patent/AU2009289646B2/en not_active Ceased
- 2009-09-03 EP EP09812245A patent/EP2328874A4/en not_active Withdrawn
- 2009-09-03 KR KR1020117007534A patent/KR20110050708A/ko active IP Right Grant
- 2009-09-03 WO PCT/US2009/055948 patent/WO2010028190A2/en active Application Filing
- 2009-09-03 US US12/553,863 patent/US8193234B2/en not_active Expired - Fee Related
- 2009-09-03 CA CA2736117A patent/CA2736117C/en active Active
- 2009-09-03 CN CN201410075960.4A patent/CN103819419B/zh active Active
- 2009-09-03 EP EP09812246A patent/EP2328879A4/en not_active Withdrawn
- 2009-09-03 JP JP2011526210A patent/JP2012502049A/ja active Pending
- 2009-09-03 JP JP2011526211A patent/JP2012502050A/ja active Pending
- 2009-09-03 MX MX2011002450A patent/MX2011002450A/es active IP Right Grant
- 2009-09-04 TW TW098130010A patent/TW201018463A/zh unknown
- 2009-09-04 AR ARP090103415A patent/AR073548A1/es unknown
- 2009-09-04 TW TW098130011A patent/TWI377200B/zh not_active IP Right Cessation
- 2009-09-04 US US12/554,737 patent/US8344012B2/en not_active Expired - Fee Related
-
2011
- 2011-02-27 IL IL211428A patent/IL211428A0/en unknown
- 2011-02-27 IL IL211429A patent/IL211429A/en active IP Right Grant
- 2011-03-02 ZA ZA2011/01626A patent/ZA201101626B/en unknown
-
2012
- 2012-02-07 HK HK12101146.7A patent/HK1160843A1/xx unknown
- 2012-05-23 ZA ZA2012/03779A patent/ZA201203779B/en unknown
- 2012-06-01 ZA ZA2012/04031A patent/ZA201204031B/en unknown
- 2012-06-04 US US13/488,191 patent/US20130040963A1/en not_active Abandoned
-
2014
- 2014-09-26 JP JP2014196668A patent/JP5918327B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR073548A1 (es) | Compuestos derivados de diazol y triazol, composiciones y uso de los mismos para modular los niveles de acido urico | |
RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
RU2472797C2 (ru) | ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА | |
CA2443950A1 (en) | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | |
AR071739A1 (es) | Inhibidores de transcriptasa reversa | |
RU2009127095A (ru) | Новые оксадиазольные соединения | |
RU2009105826A (ru) | 2,4-ди(ариламино)питимидин-5-карбоксамидные соединения в качестве ингибиторов jak-киназ | |
JP2012522729A5 (es) | ||
RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
RU2016108987A (ru) | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора | |
RU2014153627A (ru) | Имидазо[1, 2-]пиридазиновые производные как ингибиторы киназ | |
AR062427A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
WO2010138652A4 (en) | Methods for treating kaposi sarcoma | |
EA200970670A1 (ru) | Производные 3-амино-пирроло[3,4-c]пиразол-5(1h,4h,6h)-карбальдегида в качестве ингибиторов ркс | |
AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
RU2011103454A (ru) | Бициклические гетероциклы в качестве ингибиторов киназы мек | |
PE20000568A1 (es) | Derivados de isotiazol utiles como agentes anticancerosos | |
JP2013531029A5 (es) | ||
RU2010117156A (ru) | Гетероциклические соединения в качестве антагонистов crth2 рецептора | |
WO2012003405A4 (en) | Sgc stimulators | |
RU2013126041A (ru) | Пиразолопиридины и пиразолопиридины и их применение в качестве ингибиторов tyk2 | |
RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
RU2007102281A (ru) | 5-аза-7-деазапуриновые производные для лечения заболеваний, связанных с flaviviridae | |
RU2012141536A (ru) | Имидазопиридины, композиции и способы применения | |
RU2011124304A (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |